Tumour Bed Boost May Reduce QoL After Breast-Conserving Therapy
Patients with non-low-risk breast cancer in situ may experience poorer functional and cosmetic outcomes with use of tumour bed radiotherapy boost during breast-conserving therapy
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Patients with non-low-risk breast cancer in situ may experience poorer functional and cosmetic outcomes with use of tumour bed radiotherapy boost during breast-conserving therapy
Switching to a vegetable-enriched diet does not reduce the likelihood of early prostate cancer progressing
From San Antonio Breast Cancer Symposium 2022:
The phase II TRIO-US B-12 TALENT clinical trial has shown that people with hormone-receptor-positive, HER2-low localised breast cancer may benefit from neoadjuvant trastuzumab deruxtecan
From EBCC 2022:
Neoadjuvant therapy achieves a complete response in the ductal carcinoma in situ component of invasive breast cancer in approximately half of cases
From ESMO Congress 2022:
The PEARLS/KEYNOTE-091 trial points to a disease-free survival advantage with use of adjuvant pembrolizumab after complete resection of stage IB–IIIA NSCLC irrespective of PD-L1 expression
From ESMO Congress 2022:
Around half of patients with resectable cutaneous squamous cell carcinoma achieved a pathological complete response after 12 weeks of neoadjuvant cemiplimab
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.